15th May 2019
siRNA’s are functional double stranded RNA molecules which can be used to control gene expression by targeting a messenger RNA and promoting its degradation. One of the challenges in the therapeutic application of siRNA’s is targeting and delivery of the siRNA, to the cell / tissue of interest. Various adjuvants have been tested […]
15th May 2019
23rd April 2019
We have often shown that aptamers make ideal ‘capture reagents’ for use in target specific affinity chromatography. Their flexible structure makes aptamers ideally suited for the specific binding and controlled release of their target, even in the presence of complex matrixes such as cell lysates or plasma.
During the aptamer selection process, we can […]
16 April 2019
Amyloid fibrils are misfolded proteins which have assembled to form insoluble aggregates in the form of fibers that are resistant to degradation. Amyloid formation is often associated with a disease that is specific to the proteins or localisation of the aggregate. Well known examples of amyloid diseases include Alzheimer’s disease, Diabetes type 2 […]
9th April 2019
Changes in the glycosylation pattern of cell surface and secreted glycoproteins are common in malignant transformations and cancer progression, (1). Prostate-specific antigen (PSA), is a glycoprotein enzyme secreted by the prostate gland that is often used for diagnosing and predicting progression of prostate cancer in men. Recent advances in the field of glycobiology […]
2nd April 2019
Post Translational Modifications (PTM) are biochemical variations of cetain amino acids made to a protein after biosynthesis. These modifications diversify the proteome and play a fundamental role in regulation and targeting of proteins, their interactions with other molecules, as well as their structure, activity and function. Common types of post-translational modifications include phosphorylation, […]
19th October 2018.
This month data on our new improved delivery standard, webinar with Pall ForteBio, and interesting applications in targeted treatment and environmental detection of small molecules.
Following on from a successful Series A investment and lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to […]
3rd October 2018
Proprietary process with validated improvement in delivery and performance
OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of OptimersTM – the new standard for our custom development services.
Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]
24th September 2018
Aptamer Group has had a busy summer growing and preparing to launch a disruptive aptamer approach that will create better opportunities and results for our collaborators. We will be available and sharing information at the following events in October:
1 October 2018-Milner Therapeutics Symposium, Cambridge UK
As a Milner Therapeutics Institute Alliance Partner we will […]
29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]
9th August 2018
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]